- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01704937
Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum
Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile-infected recipient, and has long been a successful approach to recurrent/refractory C. difficile. The purpose of this project is to generate a frozen FMT inoculum from well-screened healthy volunteer donors which can be used repeatedly, particularly in those who do not have a healthy intimate partner or other related donor. Delivery of FMT has been performed colonoscopically, by fecal retention enema, or by the nasogastric route. This study will evaluate the safety and secondarily the efficacy of a frozen inoculum administered by nasogastric tube vs administered by colonoscope.
Subjects with recurrent/relapsing C. difficile infection (10 per group) will receive FMT via either:
- colonoscopy
- NGT
The primary endpoint is assessment of safety as measured by clinical events (GI, procedural, systemic). Efficacy will be defined as a resolution of diarrhea off antibiotics for C. difficile, in the absence of a need for OTHER systemic antibiotics, i.e. resumption of a normal bowel status for the individual. Secondary efficacy endpoints include weight, subjective well-being and relative clinical improvement per standardized questionnaire, and subject qualitative assessment of, and satisfaction with, the transplant procedures. Subjects will be monitored for clinical safety by history and standard exams and the follow-up questionnaire as well as followed closely by phone and in person.
연구 개요
연구 유형
등록 (예상)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Patients with recurrent or relapsing CDI defined as EITHER(13):
- At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic (e.g. rifaximin, nitazoxanide).
- At least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity.
- Willingness to accept risk of unrelated donor stool
- Willingness to be randomized to NGT vs. colonoscopic delivery.
- Able to consent for self, or parental assent/child assent as age appropriate.
Exclusion Criteria:
- Anatomic contraindication to NGT
- Delayed gastric emptying syndrome
- Known chronic aspiration
- Contraindication to colonoscopy (ASA 4 or more)
- High risk of bacterial translocation (Immunosuppression, cirrhosis etc)
- Pregnant or breastfeeding women
- Acute unrelated infection or comorbid illness exaccerbation
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Colonoscopy
Fecal microbiota transplant ("stool transplant") from healthy, unrelated donor via colonoscopy
|
Reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube
|
|
실험적: Nasogastric Tube (NGT)
Fecal microbiota transplant ("stool transplant") from healthy, unrelated donor via NGT
|
Reconstitution of normal flora by a "stool transplant" from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety
기간: up to 6 mo post FMT
|
Safety is assessed by clinical symptoms, exam, signs (GI and systemic)
|
up to 6 mo post FMT
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Efficacy
기간: 3 months
|
Efficacy is defined as resolution of C. Difficile signs and symptoms off antibiotics for C. difficile
|
3 months
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Elizabeth L Hohmann, MD, Massachusetts General Hospital
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2012-P-001657
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .